Lucatumumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Lucatumumab
Accession Number
DB06360
Description
Not Available
Type
Biotech
Groups
Investigational
Synonyms
  • Lucatumumab
External IDs
  • CHIR-12.12
  • HCD-122
  • HCD122

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication

Investigated for use/treatment in leukemia (lymphoid), multiple myeloma, and lymphoma (unspecified).

Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action

HCD122 is a fully human, antagonist antibody that targets the CD40 antigen. HCD122 binds to tumor cells that express CD40 and antagonizes (prevents) CD40 ligand-mediated growth and survival of malignant B cells. Based on preclinical data, HCD122 also induces antibody-dependent cellular cytotoxicity (ADCC), killing CD40 expressing tumor cells by immune effector cells. This dual mechanism of action makes HCD122 a drug candidate with potential for the treatment of B-cell malignancies.

TargetActionsOrganism
UTumor necrosis factor receptor superfamily member 5Not AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Lucatumumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Lucatumumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lucatumumab.
AlirocumabThe risk or severity of adverse effects can be increased when Lucatumumab is combined with Alirocumab.
AnsuvimabThe risk or severity of adverse effects can be increased when Lucatumumab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Lucatumumab is combined with Anthrax immune globulin human.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Lucatumumab is combined with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lucatumumab.
Asfotase alfaThe risk or severity of adverse effects can be increased when Lucatumumab is combined with Asfotase alfa.
AtezolizumabThe risk or severity of adverse effects can be increased when Lucatumumab is combined with Atezolizumab.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
P0EP9VFC4R
CAS number
903512-50-5

References

General References
Not Available
Wikipedia
Lucatumumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentFollicular Lymphoma (FL)1
1CompletedTreatmentMultiple Myeloma (MM)1
1TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL)1
1, 2CompletedTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Ubiquitin protein ligase binding
Specific Function
Receptor for TNFSF5/CD40LG. Transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglobulin secretion.
Gene Name
CD40
Uniprot ID
P25942
Uniprot Name
Tumor necrosis factor receptor superfamily member 5
Molecular Weight
30618.76 Da

Drug created on March 19, 2008 16:27 / Updated on February 21, 2021 18:52